Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
S
Sajjad A. Bhatti
Medical Director of Thoracic Cancers
Also affiliated: St. Luke's University Health Network (2025); University of Arkansas Medical Center (2022); St. Luke's Hospital (2025)
2 h-index
5 pubs
19 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Sajjad A. Bhatti's research focuses on the treatment and outcomes of thoracic cancers, particularly non-small-cell lung cancer. His work has investigated the real-world survival rates of patients receiving immune checkpoint inhibitors compared to chemotherapy, especially in older individuals with synchronous brain metastases. Bhatti has also explored the broader implications of immune checkpoint inhibitors, including their associated cardiotoxicity. His research interests extend to the stem cell theory of cancer and its translational research potential, as well as specific cancer types like triple-negative breast cancer. Bhatti collaborates with researchers at the University of Arkansas for Medical Sciences, including Alan Baltz, Jacob T. Painter, Chenghui Li, and Jun Ying, with whom he has co-authored multiple publications.
Metrics
- h-index: 2
- Publications: 5
- Citations: 19
Positions
-
Medical Director of Thoracic Cancers 2025–presentSt. Luke's Hospital Hematology/Medical Oncology ORCID
-
Medical Director of Thoracic Cancers publications 2022–2025University of Arkansas for Medical Sciences ORCID
-
Assistant Professor/Thoracic Medical Oncology 2020–2025University of Arkansas for Medical Sciences Hematology/Medical Oncology ORCID
Selected Publications
-
Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis (2025)
-
An example of long-term remission in oligorecurrent relapsed small-cell lung cancer, following single modality radiation therapy (2025)
-
Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation. (2025)
-
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide. (2025)
-
Survival and safety of two year-fixed duration vs continuous immune checkpoint inhibitor therapy in advanced or metastatic NSCLC: A systematic review. (2025)
-
Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse (2024)
-
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)
-
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)
-
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023)
-
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows. (2023)
-
Exploring the association between medical marijuana cardholder status and antiemetic overuse. (2023)
-
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench (2022)
-
A RARE CASE OF DESMOPLASTIC SMALL ROUND CELL TUMOR WITH LEPTOMENINGEAL CARCINOMATOSIS (2022)
-
Immune Checkpoint Inhibitors—Associated Cardiotoxicity (2022)
Collaboration Network
Top Collaborators
Chenghui Li
University of Arkansas for Medical Sciences
4 shared publications
In database
- Immune Checkpoint Inhibitors—Associated Cardiotoxicity
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Alan Baltz
University of Arkansas for Medical Sciences
3 shared publications
In database
- Exploring the association between medical marijuana cardholder status and antiemetic overuse.
- Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows.
- Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse
Ruchira Mahashabde
University of Arkansas for Medical Sciences (US)
3 shared publications
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Bradley C. Martin
University of Arkansas for Medical Sciences
3 shared publications
In database
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Jacob T. Painter
University of Arkansas for Medical Sciences
3 shared publications
In database
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Analiz Rodriguez
University of Arkansas for Medical Sciences
3 shared publications
In database
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Jun Ying
University of Colorado Anschutz Medical Campus
3 shared publications
In database
- Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
- Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis
Sunny Singh
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Konstantinos Arnaoutakis
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Sindhu Janarthanam Malapati
University of Arkansas for Medical Sciences
2 shared publications
In database
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Omar Atiq
University of Arkansas for Medical Sciences (US)
2 shared publications
- Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care
Cheng Peng
University of Arkansas for Medical Sciences
2 shared publications
In database
- Exploring the association between medical marijuana cardholder status and antiemetic overuse.
- Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse
Laura E. Gressler
University of Arkansas for Medical Sciences
2 shared publications
In database
- Exploring the association between medical marijuana cardholder status and antiemetic overuse.
- Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse
Kanna Lewis
University of Arkansas for Medical Sciences
2 shared publications
In database
- Exploring the association between medical marijuana cardholder status and antiemetic overuse.
- Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse
Anne Bellon
Debiopharm (Switzerland) (CH)
2 shared publications
- Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients (pts) with recurrent small cell lung cancer (SCLC): Determination of recommended dose (RD) from a phase 1 escalation.
- In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide.
Similar Researchers
Based on overlapping research topics
Daphne Macbruce
Arkansas Colleges of Health Education
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Reports
Anuradha Kunthur
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Medical Case Reports
Health disparities and outcomes
Zainab O. Atiq
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Health disparities and outcomes
Tanvi Harishbhai Patel
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Reports
Marian Symmes Johnson
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Cancer Treatment and Pharmacology
Medical Case Reports
Jaskirat Sethi
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Medical Case Reports
Health disparities and outcomes